论文部分内容阅读
目的探讨低剂量标准三联疗法根治Ｈｐ感染及对胃粘膜病变的影响．方法Ｈｐ相关性慢性胃炎患者共７３例，其中男４２例，女３１例，年龄１８岁～６２岁，均给予低剂量标准三联疗法治疗，观察其对Ｈｐ根治率．同时观察治疗前后胃粘膜病理变化．结果低剂量标准三联疗法既保持了较高根治率（８４６％，５５／６５），又降低了副作用；对胃粘膜炎性病变具有明显治疗作用，其中活动性炎症、血管瘀血和肠上皮化生消失率依次为８８９％（１６／１８），８１８％（９／１１）和６６７％（３／９）；非活动性炎症亦表现为治疗后退级或减轻，其中Ⅲ级炎症消失率为８１８％（１８／２２）；但对萎缩或增生性病变无显著疗效．结论低剂量标准三联疗法是治疗Ｈｐ相关性慢性胃炎疗效较高、价廉、副作用较少的Ｈｐ根治方法，宜早期进行
Objective To investigate the effects of low-dose triple therapy in treating Hp infection and gastric mucosal lesions. Methods A total of 73 Hp-related chronic gastritis patients, including 42 males and 31 females, ranging in age from 18 to 62 years old, were given low-dose triple therapy and the cure rate of Hp was observed. At the same time observe the pathological changes of gastric mucosa before and after treatment. Results Low dose standard triple therapy not only maintained a high cure rate (846%, 55/65) but also reduced the side effects. It had a significant therapeutic effect on inflammatory lesions of gastric mucosa, including active inflammation, blood stasis and intestine The rates of epithelial metaplasia and disappearance were 889% (16/18), 818% (9/11) and 667% (3/9), respectively. Inactivation of inflammation also showed retrogression or reduction after treatment, The grade Ⅲ inflammation disappearance rate was 818% (18/22), but no significant effect on atrophy or proliferative lesions. Conclusion Low-dose standard triple therapy is a radical treatment of Hp-related chronic gastritis with high efficacy, low cost and less side effects and should be performed early